The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

49 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.EBI
Novartis Pharma
Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors.EBI
Novartis Institutes For Biomedical Research
Buried Hydrogen Bond Interactions Contribute to the High Potency of Complement Factor D Inhibitors.EBI
University Of Michigan
Inhibitors of factor d may provide a treatment for age-related macular degeneration.EBI
Therachem Research Medilab (India)
Factor D Inhibitors for the Treatment of AMD: Patent Highlight.EBI
TBA
Scaffold hopping via ring opening enables identification of acyclic compounds as new complement Factor D inhibitors.EBI
Biocryst Pharmaceuticals
Discovery and Optimization of Novel SUCNR1 Inhibitors: Design of Zwitterionic Derivatives with a Salt Bridge for the Improvement of Oral Exposure.EBI
Novartis Institutes For Biomedical Research
Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye.EBI
Taipei Medical University
Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach.EBI
Novartis Institutes For Biomedical Research
Discovery of 4-((2 S,4 S)-4-Ethoxy-1-((5-methoxy-7-methyl-1 H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated DiseasesEBI
Novartis Institutes For Biomedical Research
Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway.EBI
Novartis Institutes For Biomedical Research
Ligand-Based Fluorine NMR Screening: Principles and Applications in Drug Discovery Projects.EBI
Lavis
Chemical Approaches to Modulating Complement-Mediated Diseases.EBI
The University Of Queensland
Discovery and Design of First Benzylamine-Based Ligands Binding to an Unlocked Conformation of the Complement Factor D.EBI
Novartis Pharma